Gamble Jones Investment Counsel’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $911K | Hold |
5,700
| – | – | 0.07% | 117 |
|
|
2022
Q3 | $802K | Hold |
5,700
| – | – | 0.07% | 121 |
|
|
2022
Q2 | $831K | Hold |
5,700
| – | – | 0.06% | 120 |
|
|
2022
Q1 | $924K | Hold |
5,700
| – | – | 0.06% | 124 |
|
|
2021
Q4 | $1.08M | Hold |
5,700
| – | – | 0.06% | 116 |
|
|
2021
Q3 | $1.15M | Sell |
5,700
-300
| -5% | -$63K | 0.08% | 112 |
|
|
2021
Q2 | $1.21M | Hold |
6,000
| – | – | 0.08% | 111 |
|
|
2021
Q1 | $1.05M | Hold |
6,000
| – | – | 0.07% | 120 |
|
|
2020
Q4 | $1.02M | Hold |
6,000
| – | – | 0.07% | 118 |
|
|
2020
Q3 | $972K | Hold |
6,000
| – | – | 0.07% | 118 |
|
|
2020
Q2 | $978K | Hold |
6,000
| – | – | 0.08% | 110 |
|
|
2020
Q1 | $768K | Hold |
6,000
| – | – | 0.07% | 118 |
|
|
2019
Q4 | $837K | Hold |
6,000
| – | – | 0.07% | 135 |
|
|
2019
Q3 | $708K | Hold |
6,000
| – | – | 0.06% | 137 |
|
|
2019
Q2 | $774K | Hold |
6,000
| – | – | 0.07% | 131 |
|
|
2019
Q1 | $771K | Hold |
6,000
| – | – | 0.07% | 131 |
|
|
2018
Q4 | $664K | Hold |
6,000
| – | – | 0.07% | 135 |
|
|
2018
Q3 | $816K | Hold |
6,000
| – | – | 0.08% | 135 |
|
|
2018
Q2 | $720K | Hold |
6,000
| – | – | 0.07% | 140 |
|
|
2018
Q1 | $722K | Hold |
6,000
| – | – | 0.07% | 140 |
|
|
2017
Q4 | $748K | Hold |
6,000
| – | – | 0.07% | 137 |
|
|
2017
Q3 | $805K | Hold |
6,000
| – | – | 0.08% | 134 |
|
|
2017
Q2 | $754K | Hold |
6,000
| – | – | 0.08% | 143 |
|
|
2017
Q1 | $714K | Hold |
6,000
| – | – | 0.08% | 141 |
|
|
2016
Q4 | $645K | Hold |
6,000
| – | – | 0.07% | 150 |
|
|
2016
Q3 | $691K | Hold |
6,000
| – | – | 0.07% | 143 |
|
|
2016
Q2 | $614K | Hold |
6,000
| – | – | 0.07% | 148 |
|
|
2016
Q1 | $622K | Hold |
6,000
| – | – | 0.07% | 147 |
|
|
2015
Q4 | $762K | Hold |
6,000
| – | – | 0.08% | 136 |
|
|
2015
Q3 | $686K | Hold |
6,000
| – | – | 0.08% | 144 |
|
|
2015
Q2 | $809K | Hold |
6,000
| – | – | 0.08% | 139 |
|
|
2015
Q1 | $777K | Hold |
6,000
| – | – | 0.08% | 146 |
|
|
2014
Q4 | $692K | Hold |
6,000
| – | – | 0.07% | 151 |
|
|
2014
Q3 | $635K | Hold |
6,000
| – | – | 0.07% | 149 |
|
|
2014
Q2 | $572K | Hold |
6,000
| – | – | 0.06% | 159 |
|
|
2014
Q1 | $546K | Hold |
6,000
| – | – | 0.06% | 153 |
|
|
2013
Q4 | $531K | Hold |
6,000
| – | – | 0.06% | 155 |
|
|
2013
Q3 | $496K | Hold |
6,000
| – | – | 0.06% | 157 |
|
|
2013
Q2 | $411K | Buy |
+6,000
| New | +$417K | 0.05% | 175 |
|
Other funds holding BBH
TIA
MJRIC
PGFC
CIG
Gamble Jones Investment Counsel's BBH Position: Q4 2022 in Review
Gamble Jones Investment Counsel held its VanEck Biotech ETF (BBH) position steady in Q4 2022 at 5,700 shares worth $911K. The position accounts for 0.07% of the portfolio, ranked #117.
Gamble Jones Investment Counsel first reported a position in BBH in Q2 2013 and has held it in 39 quarters since. The position peaked at $1.21M in Q2 2021. 120 funds tracked by Wall St. Rank hold BBH as of Q4 2022.
- Gamble Jones Investment Counsel held 5,700 shares of VanEck Biotech ETF worth $911K as of Q4 2022.
- Gamble Jones Investment Counsel left its VanEck Biotech ETF share count unchanged in Q4 2022.
- VanEck Biotech ETF made up 0.07% of Gamble Jones Investment Counsel's portfolio in Q4 2022, its #117 holding.
- Gamble Jones Investment Counsel first reported a position in VanEck Biotech ETF in Q2 2013 and has held it in 39 quarters since.
- Gamble Jones Investment Counsel's VanEck Biotech ETF position peaked at $1.21M in Q2 2021.
- 120 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2022.
Based on Gamble Jones Investment Counsel's 13F filing for Q4 2022, filed 8 Feb 2023.